Creo Medical has reported strong H1/20A and post-period performance. While COVID has impacted the company's ability to market its products in hospitals, at commercial events and provide training during 2020 Creo has continued to book commercial orders, provide remote training, receive regulatory clearances for new devices and complete a significant acquisition. We believe that as healthcare systems begin to recover from the impact of the pandemic, the benefits of Creo's technology could come to ....
23 Sep 2020
Cenkos: Creo Medical Group Plc -- Progress despite COVID
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Cenkos: Creo Medical Group Plc -- Progress despite COVID
Creo Medical Group Plc (CREO:LON) | 34.2 -0.2 (-1.4%) | Mkt Cap: 123.8m
- Published:
23 Sep 2020 -
Author:
Chris Donnellan -
Pages:
5
Creo Medical has reported strong H1/20A and post-period performance. While COVID has impacted the company's ability to market its products in hospitals, at commercial events and provide training during 2020 Creo has continued to book commercial orders, provide remote training, receive regulatory clearances for new devices and complete a significant acquisition. We believe that as healthcare systems begin to recover from the impact of the pandemic, the benefits of Creo's technology could come to ....